Singlin
Generic Name
Linagliptin
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| singlin 2 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Singlin 2 mg Tablet contains Linagliptin, an oral medicine used to control blood sugar levels in adults with type 2 diabetes mellitus. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Uses & Indications
Dosage
Adults
The recommended dose is 2 mg once daily. It can be taken with or without food.
Elderly
No dose adjustment is required based on age.
Renal_impairment
No dose adjustment is required in patients with renal impairment (including end-stage renal disease on dialysis).
How to Take
Take the tablet orally once daily, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Linagliptin selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the inactivation of incretin hormones like GLP-1 and GIP. By inhibiting DPP-4, linagliptin increases the levels of active incretin hormones, which, in turn, increase glucose-dependent insulin release from pancreatic beta cells and decrease glucagon secretion from pancreatic alpha cells, thereby reducing hepatic glucose production.
Pharmacokinetics
Onset
Within hours of administration, with sustained DPP-4 inhibition observed.
Excretion
Mainly eliminated via the enterohepatic system (bile and feces), with a minor portion excreted renally.
Half life
Effective half-life for DPP-4 inhibition is approximately 12 hours, while the terminal elimination half-life is greater than 100 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations reached in approximately 1.5 hours. Absolute bioavailability is around 30%.
Metabolism
Minimal metabolism, primarily excreted unchanged. A small fraction undergoes metabolism via CYP3A4, but it is not a major elimination pathway.
Side Effects
Contraindications
- Hypersensitivity to linagliptin or any of its excipients.
- Patients with type 1 diabetes mellitus.
- Patients with diabetic ketoacidosis.
Drug Interactions
Rifampicin
Concomitant use with strong CYP3A4 inducers (e.g., rifampicin) may decrease linagliptin exposure, potentially reducing efficacy. Consider alternative anti-diabetic agents.
P-glycoprotein inhibitors
No clinically meaningful interactions observed with P-glycoprotein inhibitors.
Storage
Store below 30°C in a dry place, away from light and moisture.
Overdose
In case of an overdose, symptomatic treatment is recommended. Linagliptin is not significantly dialyzable.
Pregnancy & Lactation
Use during pregnancy should be avoided unless clearly necessary. It is unknown whether linagliptin is excreted in human milk; a decision to discontinue nursing or the drug should be made considering the importance of the drug to the mother.
Side Effects
Contraindications
- Hypersensitivity to linagliptin or any of its excipients.
- Patients with type 1 diabetes mellitus.
- Patients with diabetic ketoacidosis.
Drug Interactions
Rifampicin
Concomitant use with strong CYP3A4 inducers (e.g., rifampicin) may decrease linagliptin exposure, potentially reducing efficacy. Consider alternative anti-diabetic agents.
P-glycoprotein inhibitors
No clinically meaningful interactions observed with P-glycoprotein inhibitors.
Storage
Store below 30°C in a dry place, away from light and moisture.
Overdose
In case of an overdose, symptomatic treatment is recommended. Linagliptin is not significantly dialyzable.
Pregnancy & Lactation
Use during pregnancy should be avoided unless clearly necessary. It is unknown whether linagliptin is excreted in human milk; a decision to discontinue nursing or the drug should be made considering the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date
Availability
Available in pharmacies nationwide
Approval Status
Approved by regulatory authorities (e.g., FDA/DGDA)
Patent Status
Generics available; Original patent might vary by region
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of linagliptin in improving glycemic control and reducing cardiovascular risk in patients with type 2 diabetes.
Lab Monitoring
- Regular monitoring of blood glucose levels (HbA1c) is recommended to assess glycemic control.
- Monitoring of renal function may be considered, although no dose adjustment is required in renal impairment.
Doctor Notes
- Monitor patients for symptoms of pancreatitis (e.g., severe abdominal pain, nausea, vomiting) and bullous pemphigoid.
- Educate patients on hypoglycemia awareness, especially when linagliptin is used in combination with sulfonylureas or insulin.
Patient Guidelines
- Take Singlin 2 mg Tablet exactly as prescribed by your doctor.
- Do not stop taking this medicine without consulting your doctor, even if you feel well.
- Maintain a healthy diet and regular exercise as advised by your healthcare provider.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once.
Driving Precautions
Linagliptin has no or negligible influence on the ability to drive and use machines. However, patients should be advised of the risk of hypoglycemia when used in combination with sulfonylureas or insulin, which could affect driving ability.
Lifestyle Advice
- Follow a balanced diet low in sugar and saturated fats.
- Engage in at least 30 minutes of moderate-intensity physical activity most days of the week.
- Regularly monitor your blood sugar levels at home as instructed by your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Singlin Brand
Other medicines available under the same brand name
